Alpha Omega Trial: Study of Omega-3 Fatty Acids and Coronary Mortality
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00127452 |
|
Recruitment Status :
Completed
First Posted : August 5, 2005
Last Update Posted : July 7, 2010
|
Sponsor:
Wageningen University
Collaborators:
Netherlands Heart Foundation
National Heart, Lung, and Blood Institute (NHLBI)
Unilever R&D
Information provided by:
Wageningen University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The Alpha Omega Trial is a randomized, placebo-controlled, double-blind dietary intervention study in 4837 postmyocardial infarction patients in the Netherlands to examine whether incidence of cardiovascular diseases during 40 months of follow-up can be prevented by low doses of omega-3 polyunsaturated fatty acids. The key objectives are:
- to examine the effect of low-dose supplementation (400 mg/day) of eicosapentaenoic acid and docosahexaenoic acid on incidence of cardiovascular diseases; and
- to examine the effect of low-dose supplementation (2 g/day) of alpha-linolenic acid on incidence of cardiovascular diseases.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cardiovascular Diseases | Dietary Supplement: margarine spread | Not Applicable |
Whether dietary omega-3 (or n-3) polyunsaturated fatty acids are causally related to risk of cardiovascular diseases (CVD) is a major, unresolved question in preventive cardiology. Essential n-3 fatty acids are eicosapentaenoic acid (EPA; C20:5, n-3) and docosahexaenoic acid (DHA; C22:6, n-3) on one hand, and their parent compound alpha-linolenic acid (ALA; C18:3, n-3) on the other hand. The intake of n-3 fatty acids is below recommended levels in most Western populations. The Alpha Omega Trial is a randomized, double-blind, placebo-controlled study of the effect of low-dose supplementation of ALA and EPA-DHA on CVD. A total of 4837 Dutch men and women aged 60-80 years who had a myocardial infarction in the past 10 years are randomly allocated to 2 g/d of ALA, 400 mg/d of EPA-DHA, 2 g/d ALA + 400 mg/d EPA-DHA, or placebo, for 40 months. Increased intake of n-3 fatty acids is achieved through daily use of 20 g of margarine on bread. Margarines for all treatment groups are similar in taste and appearance. The primary outcome of the trial is 'major cardiovascular events', which comprises incident CVD and cardiac interventions (PCI and CABG) during follow-up. Secondary endpoints are incident CVD, fatal CVD, fatal CHD and all-causes mortality. Complete follow-up for vital status is achieved. Cause-specific mortality is coded by an independent Endpoint Adjudication Committee. Physical examination, blood sampling and data collection on diet and lifestyle are performed in all subjects at baseline, in 810 randomly selected subjects after 20 months of intervention, and in 58% of the cohort at the end of follow-up. Cardiovascular health, serious adverse events, lifestyle, fish intake and margarine use are monitored in all subjects by yearly telephone interviews. Compliance is continuously monitored by registration of margarine tubs. An objective biomarker of compliance (i.e. plasma n-3 fatty acids) is obtained in randomly selected subjects at baseline and after 20 and 40 months of intervention. The Alpha Omega Trial could provide a sound scientific basis for dietary recommendations on intake of ALA and EPA-DHA, in order to reduce the burden of cardiovascular diseases.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 4837 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Alpha Omega Trial: A Randomised, Placebo Controlled, Double Blind Intervention Study of the Effect of Low Doses of Omega-3 Fatty Acids on Cardiovascular Diseases in Patients With a History of Myocardial Infarction |
| Study Start Date : | April 2002 |
| Actual Primary Completion Date : | November 2009 |
| Actual Study Completion Date : | June 2010 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Heart Attack
Drug Information available for:
Omega-3 Fatty Acids
| Arm | Intervention/treatment |
|---|---|
|
Experimental: EPA + DHA
Margarine spread that yields 400 mg of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) per day for average margarine use of 20 grams per day
|
Dietary Supplement: margarine spread
Daily use of margarine spread (approximately 20 grams) during 40 months |
|
Experimental: ALA
Margarine spread that yields 2 grams of alpha-linolenic acid (ALA) per day for average margarine use of 20 grams per day
|
Dietary Supplement: margarine spread
Daily use of margarine spread (approximately 20 grams) during 40 months |
|
Experimental: EPA + DHA plus ALA
Margarine spread that yields 400 mg of EPA + DHA per day plus 2 grams of ALA per day, for average margarine use of 20 grams per day
|
Dietary Supplement: margarine spread
Daily use of margarine spread (approximately 20 grams) during 40 months |
|
Placebo Comparator: Placebo
Margarine spread that contains no EPA, DHA or ALA (exchanged for oleic acid)
|
Dietary Supplement: margarine spread
Daily use of margarine spread (approximately 20 grams) during 40 months |
Primary Outcome Measures :
- Major cardiovascular events, which comprises fatal cardiovascular diseases (CVD), non-fatal myocardial infarction, non-fatal cardiac arrest, non-fatal stroke and cardiac interventions (PCI and CABG) [ Time Frame: monitored during intervention ]
Secondary Outcome Measures :
- Incident CVD, which comprises fatal CVD, non-fatal myocardial infarction, non-fatal cardiac arrest and non-fatal stroke [ Time Frame: monitored during intervention ]
- Fatal CVD, which comprises mortality from ischaemic heart disease, fatal cardiac arrest, sudden death undefined, mortality from heart failure and fatal stroke [ Time Frame: monitored during intervention ]
- Fatal CHD, which comprises mortality from ischaemic heart disease, mortality from cardiac arrest, and sudden death undefined [ Time Frame: monitored during intervention ]
- All-causes mortality [ Time Frame: monitored during intervention ]
- The composite of sudden death undefined and nonfatal and fatal cardiac arrest [ Time Frame: monitored during intervention ]
- The composite of sudden death undefined, nonfatal and fatal cardiac arrest, and self-reported placement of any implantable cardioverter-defibrillator, verified in medical records [ Time Frame: monitored during intervention ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 60 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Men and women
- Aged 60 through 80 y
- Verified clinically diagnosed myocardial infarction up to 10 y before randomization
- Written informed consent
Exclusion criteria:
- Living in a nursing home or other institution
- Participation in another scientific study
- Habitual margarine intake < 10 g per day
- Habitual fish intake > 150 g per day
- Habitual alcohol intake > 6 drinks per day
- Use of fish oil capsules or other supplements containing omega-3 fatty acids
- Presence of cancer with < 1 y of life expectancy
- Cognitive impairment, as indicated by the Mini Mental State Examination (score <= 21)
- Unintended weight loss > 5 kg in the past year
- Lack of facilities for cooled margarine storage at home
- Inability or unwillingness to comply with study procedures
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00127452
Locations
Show 32 study locations
Sponsors and Collaborators
Wageningen University
Netherlands Heart Foundation
National Heart, Lung, and Blood Institute (NHLBI)
Unilever R&D
Investigators
| Principal Investigator: | Daan Kromhout, PhD MPH | Wageningen University, The Netherlands |
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Daan Kromhout, Wageningen University |
| ClinicalTrials.gov Identifier: | NCT00127452 |
| Obsolete Identifiers: | NCT00139464 |
| Other Study ID Numbers: |
METC-ZWH 0552 NHF-2000T401 L01.049 5R01HL076200 ( U.S. NIH Grant/Contract ) |
| First Posted: | August 5, 2005 Key Record Dates |
| Last Update Posted: | July 7, 2010 |
| Last Verified: | July 2010 |
Keywords provided by Wageningen University:
|
alpha-linolenic acid cardiovascular diseases coronary heart disease coronary patients DHA dietary intervention dietary supplementation docosahexaenoic acid eicosapentaenoic acid EPA fish oil fish fatty acids human subjects |
ischaemic heart disease margarine marine fatty acids mortality myocardial infarction n-3 fatty acids n-3 polyunsaturated fatty acids n-3 PUFA omega-3 fatty acids omega-3 polyunsaturated fatty acids prevention randomized controlled trial secondary prevention |
Additional relevant MeSH terms:
|
Cardiovascular Diseases |